News

BEWARE OF CANCER MISINFORMATION

Our AIMS Institute oncology team is well informed about alternative cancer therapies such as ivermectin, intravenous vitamin C, mistletoe, curcumin, and mebendazole.  We help our patients sort through marketing hype, …

Unusual Suspects

Psychedelic Therapies Gain New Advocates Texas Law Magazine Written by Robin Berghaus. Art by Matthieu Bourel Published November 6, 2024 Marcus Capone served seven combat tours as a Navy …

Brain cancer update

July 12, 2024 Leanna Standish IV CURCUMIN AIMS Institute’s integrative oncology team is investigating the therapeutic effects of intravenous curcumin in treating the most aggressive type of brain cancer, …

Baneful Balms

Please see AIMS’ Integrative Primary Care Attending Physician and Registered Herbalist Dr. Duncan Lynch’s presentation on Baneful Balms: Low-Dose Herbal Formulations in Clinical Practice given at the 2023 American …

Media Advisory For Federal Appeals Court – Psilocybin Case Hearing

Link to oral arguments: https://youtu.be/39MhxZ8SQ0U Article about the hearing: https://www.marijuanamoment.net/federal-court-hears-case-challenging-dea-decision-to-deny-psilocybin-rescheduling-petition-without-consulting-health-officials/?fbclid=IwAR139IISoWU1peXCNr04xgkM3N9rgCk9OybBMI3-hxkY7AAABbyGD373YnA An interview I gave on awake.net: https://awake.net/aims-vs-dea-right-to-try-psilocybin-for-end-of-life-court-hearing-of-deas-denial-on-petition-to-reschedule-psilocybin-friday-oct-20-2023-9-am-phoenix-azhttps-youtu-be-ud1vsa69e6msitufvgxoy/ Media Advisory Right to Try and psychedelics subject matter experts are available …

Surrending To The Void

by Dan Vinkovetsky aka Danny Danko: I spoke with Dr. Alison Draisin PsyD, LMHC, lead psychotherapist and Director of Ketamine Assisted Psychotherapy Provider Training at the AIMS Institute, to …

Latest Blog Posts

Stellate Ganglion Block Effectiveness for PTSD, Anxiety, and Depression in Psychiatric Outpatients: A Retrospective Analysis

Stellate Ganglion Block Effectiveness for PTSD, Anxiety, and Depression in Psychiatric Outpatients: A Retrospective Analysis

https://scholarworks.seattleu.edu/dnp-projects/166/ The prevalences of Post-Traumatic Stress Disorder (PTSD), generalized anxiety disorder (GAD), and major depressive disorder (MDD) have risen significantly in recent years, particularly following the COVID-19 pandemic. Many individuals remain symptomatic despite conventional treatments, highlighting the need for novel, integrative interventions. Stellate Ganglion Block (SGB), a procedure targeting the cervical sympathetic chain to modulate the autonomic nervous system, has emerged as a promising therapy for treatment-resistant psychiatric symptoms. Evaluating data from the PTSD Checklist for DSM-5 (PCL-5), Generalized Anxiety Disorder-7 (GAD-7), and Patient Health Questionnaire-9 (PHQ-9), this retrospective study examined the clinical outcomes of PTSD, anxiety, and depression symptoms ...

Read More
BEWARE OF CANCER MISINFORMATION

BEWARE OF CANCER MISINFORMATION

Our AIMS Institute oncology team is well informed about alternative cancer therapies such as ivermectin, intravenous vitamin C, mistletoe, curcumin, and mebendazole.  We help our patients sort through marketing hype, wishful thinking, and the real value of some alternative treatments. We say to our cancer patients who do not trust conventional medicine to beware of misinformation on the internet.  Be discerning.  We can help. Here is a recent MEDSCAPE article on this topic. ...

Read More
AIMS INSTITUTE’S COGNITIVE DECLINE PROTOCOL

AIMS INSTITUTE’S COGNITIVE DECLINE PROTOCOL

LJ STANDISH AND DAVID JAMES Dr. Standish and her team can help improve brain function, improve memory and slow cognitive decline in Alzheimer’s disease.  Please make an appointment to start.  Call 206-420-1321.  Scientific Rationale A protocol incorporating low-dose lithium orotate, Lion’s Mane mushroom extract, NADH, transcranial magnetic stimulation (TMS), and blood sugar regulation counseling is scientifically rational for treating cognitive decline based on mechanistic, preclinical, and emerging human studies. Low-Dose Lithium Orotate (5 mg/day) Recent brain tissue studies link low brain lithium to the onset and progression of Alzheimer’s disease, with deficiency accelerating synaptic loss and cognitive decline. Low-dose lithium orotate has ...

Read More
Call Us Text Us
Skip to content